Drug-Resistant Bacteria Can Raise Sepsis Risk
By LabMedica International staff writers Posted on 11 May 2017 |
Image: Research shows that when drug-resistant bacteria such as e. coli enter the bloodstream, it can raise a person’s risk for sepsis (Photo courtesy of the CDC).
Sepsis affects an estimated 30 million people worldwide each year and without quick treatment, it can lead to multiple organ failure and death. Treating sepsis can be even more difficult if the bacteria responsible are resistant to antibiotics.
In some cases bacteria may be spreading from the bowel or urinary tract into the bloodstream, while in others the bacteria found in patients’ urine or stool samples could be transferring their ability to resist antibiotics to other bacteria in the body, which then can cause sepsis.
Scientists at the Karolinska Institutet studied 66,000 people and showed that the risk of drug resistant sepsis is highest soon after drug resistant bacteria have been detected in a patient’s urine or stool, and that this risk diminishes over time. They say their findings could help doctors diagnose drug resistant sepsis and inform treatment choices. The team studied all subjects who were found to have specific types of bacteria in their urine or stool samples in Sweden between 2007 and 2012, more than 22,000 in total. They compared them with an equivalent group of 44,000 people who had no diagnosis of extended-spectrum β-lactamase-producing Enterobacteriaceae (EPE).
The investigators focused on certain bacteria, such as Escherichia coli, that produce enzymes called extended spectrum β-lactamases. These enzymes allow bacteria to break down a variety of antibiotics including penicillin and third-generation cephalosporins. They followed the subjects for six years to find out if they subsequently developed a bloodstream infection. The data revealed that people whose bowels had been colonized previously by EPE were 57 times more likely to develop an EPE infection of the bloodstream, compared to the general population. For those with a previous finding of EPE in their urine, the risk was 113 times higher than the general population. Over the six-year study period, 2% of those with EPE in the bowel and 4% of those with a urinary tract infection went on to have a bloodstream infection with EPE. This compares to 0.02% in the general population.
Joakim Isendahl, MD, who presented the study said, “Knowing if a patient has had a previous finding of EPE, and how long ago it was, helps inform doctors on when last-resort drugs are essential, but also on when they are not needed. This is important since prudent use is imperative to keep them effective. We found that the riskiest time was in the days and weeks after the bacteria were found in the urine or stool sample, but there is still an increased risk up to three years later.” The study was presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases, held April 22-25, 2017, in Vienna, Austria.
In some cases bacteria may be spreading from the bowel or urinary tract into the bloodstream, while in others the bacteria found in patients’ urine or stool samples could be transferring their ability to resist antibiotics to other bacteria in the body, which then can cause sepsis.
Scientists at the Karolinska Institutet studied 66,000 people and showed that the risk of drug resistant sepsis is highest soon after drug resistant bacteria have been detected in a patient’s urine or stool, and that this risk diminishes over time. They say their findings could help doctors diagnose drug resistant sepsis and inform treatment choices. The team studied all subjects who were found to have specific types of bacteria in their urine or stool samples in Sweden between 2007 and 2012, more than 22,000 in total. They compared them with an equivalent group of 44,000 people who had no diagnosis of extended-spectrum β-lactamase-producing Enterobacteriaceae (EPE).
The investigators focused on certain bacteria, such as Escherichia coli, that produce enzymes called extended spectrum β-lactamases. These enzymes allow bacteria to break down a variety of antibiotics including penicillin and third-generation cephalosporins. They followed the subjects for six years to find out if they subsequently developed a bloodstream infection. The data revealed that people whose bowels had been colonized previously by EPE were 57 times more likely to develop an EPE infection of the bloodstream, compared to the general population. For those with a previous finding of EPE in their urine, the risk was 113 times higher than the general population. Over the six-year study period, 2% of those with EPE in the bowel and 4% of those with a urinary tract infection went on to have a bloodstream infection with EPE. This compares to 0.02% in the general population.
Joakim Isendahl, MD, who presented the study said, “Knowing if a patient has had a previous finding of EPE, and how long ago it was, helps inform doctors on when last-resort drugs are essential, but also on when they are not needed. This is important since prudent use is imperative to keep them effective. We found that the riskiest time was in the days and weeks after the bacteria were found in the urine or stool sample, but there is still an increased risk up to three years later.” The study was presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases, held April 22-25, 2017, in Vienna, Austria.
Latest Microbiology News
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia
- Rapid AST Platform Provides Targeted Therapeutic Results Days Faster Than Current Standard of Care
- New Analysis Method Detects Pathogens in Blood Faster and More Accurately by Melting DNA
- Rapid Sepsis Test Delivers Two Days Faster Results
- Portable Rapid PCR Diagnostic to Detect Gonorrhea and Antibiotic Susceptibility